Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial.

ABSTRACT: Neoantigens, which are derived from tumour-specific protein-coding mutations, are exempt from central tolerance, can generate robust immune responses^1,2 and can function as bona fide antigens that facilitate tumour rejection³. Here we demonstrate that a strategy that uses multi-epitope, personalized neoantigen vaccination, which has previously been tested in patients with high-risk melanoma^4-6, is feasible for tumours such as glioblastoma, which typically have a relatively low mutation load^1,7 and an immunologically 'cold' tumour microenvironment⁸. We used personalized neoantigen-targeting vaccines to immunize patients newly diagnosed with glioblastoma following surgical resection and conventional radiotherapy in a phase I/Ib study. Pa

SUBMITTER: Keskin DB 

PROVIDER: S-EPMC6546179 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature